BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth

BioMarin Pharmaceutical (BMRN) is set to report results for the quarter ended June 2025 on August 4, with consensus estimates projecting $1.03 EPS (+7.3% Y/Y) and $766.23 million in revenue (+7.6% Y/Y). Despite a recent 11.64% downward revision to consensus EPS estimates, the company's positive Zacks Earnings ESP of +1.62% combined with a Zacks Rank #3 suggests a high probability of an earnings beat, a trend supported by its consistent history of surpassing EPS forecasts. This outlook positions BMRN as a compelling earnings-beat candidate, which could significantly influence its near-term stock performance.

Analysis

BioMarin Pharmaceutical (BMRN) is approaching its August 4 earnings release with a mix of signals that warrant careful consideration. The consensus expects solid year-over-year growth, with revenues projected to rise 7.6% to $766.23 million and earnings per share (EPS) to increase 7.3% to $1.03. However, a notable headwind is the significant 11.64% downward revision of the consensus EPS estimate over the past 30 days, suggesting analysts have broadly tempered their initial optimism. Counterbalancing this is a more recent, bullish indicator: the company holds a positive Zacks Earnings ESP of +1.62%, indicating that the most recent analyst estimates are higher than the consensus. Combined with a Zacks Rank of #3 (Hold), this creates a high probability of an earnings beat, a scenario supported by BioMarin's history of surpassing EPS estimates for the last four consecutive quarters, including a 20.21% beat last quarter. The company's positive growth outlook contrasts sharply with industry peer Biogen (BIIB), which is expected to report declines in both revenue and earnings, highlighting BioMarin's relative strength within the sector.

Key Decisions for Investors

• Given the positive +1.62% Earnings ESP and a consistent history of beating forecasts, investors could anticipate a probable EPS beat, which may create a short-term trading opportunity around the August 4 report.
• The significant 11.64% downward revision in consensus EPS over the last month is a key risk factor; therefore, investors must scrutinize management's forward-looking guidance on the earnings call, as any weakness here could overshadow a headline beat.
• Consider the divergent outlooks between BioMarin and its peer Biogen (BIIB) as a potential basis for a pair trade or relative value assessment within the biomedical and genetics industry.
• While the quantitative signals point towards an earnings beat, the stock's ultimate direction will heavily depend on qualitative factors from the earnings call, making it prudent to hold existing positions rather than initiating large new ones until management's commentary is fully digested.